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One of the main consequences of inhibition of neovessel growth and vessel pruning 45 
produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence 46 
indicates that tumor cells escape from this hypoxic environment to better nourished 47 
locations, presenting hypoxia as a positive stimulus for invasion. In particular, anti-48 
VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous 49 
mouse model of pancreatic neuroendocrine cancer (PanNET), RIP1-Tag2. Here, a 50 
novel vascular targeting agent targeting Semaphorin 4D (Sema4D) demonstrated 51 
impaired tumor growth and extended survival in the RIP1-Tag2 model. Surprisingly, 52 
although there was no induction of intratumor hypoxia by anti-Sema4D therapy, the 53 
increase in local invasion and distant metastases were comparable with the ones 54 
produced by VEGFR inhibition. Mechanistically, the antitumor effect was due to an 55 
alteration in vascular function by modification of pericyte coverage involving PDGF-B. 56 
On the other hand, the aggressive phenotype involved a macrophage-derived Sema4D 57 
signaling engagement which induced their recruitment to the tumor invasive fronts and 58 
secretion of stromal derived factor 1 (SDF1) that triggered tumor cell invasive behavior 59 
via CXCR4. A comprehensive clinical validation of the targets in different stages of 60 
PanNETs demonstrated the implication of both Sema4D and CXCR4 in tumor 61 
progression. Taken together, we demonstrate beneficial anti-tumor and pro-survival 62 
effects of anti-Sema4D antibody but also unravel a novel mechanism of tumor 63 
aggressivity. This mechanism implicates recruitment of Sema4D positive macrophages 64 
to invasive fronts and their secretion of pro-invasive molecules that ultimately induce 65 




One of the main consequences of vessel pruning and inhibition of neovessel growth 70 
produced by angiogenesis inhibitors is the increased hypoxia levels produced inside 71 
the tumors. Cancer cells can live in hypoxic conditions (1), but growing evidence 72 
indicates that tumor cells may escape from this hypoxic environment to better 73 
nourished locations, presenting hypoxia as a positive stimulus for invasion (2). In fact, a 74 
strong correlation among tumor hypoxia and increased invasion, metastasis and poor 75 
patient outcome has been reported (3–5). In this context, alternative angiogenic targets 76 
such as semaphorins are beeing explored (6). 77 
 78 
Semaphorins (SEMAs) are a superfamily of secreted or membrane-associated 79 
glycoproteins implicated in axonal wiring control, angiogenesis and cancer progression. 80 
Semaphorin 4D (Sema4D) is a transmembrane protein of 150 KDa of the IV class of 81 
the subfamily of semaphorins involved in the regulation of axon guidance, cell 82 
migration in organ development and vascular morphogenesis (7–9). Three receptors 83 
are known for Sema4D: high-affinity receptor Plexin-B1 (PlxnB1), expressed in a wide 84 
variety of cell types, intermediate affinity Plexin-B2 (PlxnB2), and low-affinity receptor, 85 
CD72, mainly expressed in cells of the immune system (10,11). Sema4D is highly 86 
expressed in the membrane of most frequent solid tumors, including breast, prostate 87 
and colon (12), and also in tumor associated macrophages (TAMs), with a relevant role 88 
in tumor invasion, angiogenesis and metastasis (13). High expression levels of 89 
Sema4D have been also reported in tumor stroma (14). Due to proteolytical cleavage 90 
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by matrix metalloproteinase type 1 (MT1-MMP, also known as MMP14) a Sema4D 91 
soluble form is released (15,16), allowing to act through PlxnB1 on endothelial cells 92 
and promoting angiogenesis which permits tumors to be nourished with the necessary 93 
nutrients and oxygen to continue its growth (12). In fact, there is a completed Phase I 94 
clinical trial to evaluate the safety and tolerability of intra-venous (IV) administration of 95 
an antibody anti-Sema4D VX15/2503 (Vaccinex Inc, Rochester, NY) in patients with 96 
advanced solid tumors (ClinicalTrials.gov identifier: NCT01313065) (17).  97 
 98 
In this study, using a spontaneous mouse model of pancreatic neuroendocrine cancer 99 
(PanNET), RIP1-Tag2 mice, we describe alteration of tumor vascular function by the 100 
use of a vascular-targeting agent anti-Sema4D antibody that consequently impairs 101 
tumor growth. Unlike VEGF/R blockade, induction of intratumor hypoxia is not 102 
observed after anti-Sema4D therapy, but the increase in local invasion and distant 103 
metastases are comparable with anti-VEGFR2’s effects. This hypoxia-independent 104 
mechanism of increased aggressive phenotype is associated with recruitment of TAMs 105 
as mediators of increased invasion and dissemination of tumor cells after anti-Sema4D 106 
treatment. Mechanistically, anti-Sema4D antibody induces a Sema4D signaling 107 
engagement in the membrane of macrophages not only for their motility and 108 
recruitment to the tumor invasive fronts, but also for increased secretion of stromal 109 
derived factor 1 (SDF1). In turn, SDF1 enhances tumor cell invasive behavior via 110 
CXCR4 and triggers the malignant PanNET phenotype in anti-Sema4D treated RIP1-111 
Tag2 mice. Finally, we also present clinical evidence that support a role for Sema4D 112 
and SDF1 overexpression in human macrophages and an association of Sema4D and 113 
CXCR4 in PanNETpatients tumor progression. 114 
 115 
MATERIALS AND METHODS  116 
 117 
Animal model and Therapeutic Trials 118 
Transgenic RIP1-Tag2 mice have been previously reported (18). Animal housing, 119 
handling and all procedures were approved by our institution’s ethical committee and 120 
Government committees. Tumor volume, type, invasiveness and hemorrhagic 121 
phenotype was determined as previously described (19). Four week-long treatments in 122 
RIP1-Tag2 mice started at 12 weeks of age with: 1) Anti-Semaphorin 4D Mab67 123 
function blocking murine IgG1 antibody (anti-Sema4D) kindly provided by Vaccinex Inc, 124 
Rochester, NY (20), 2) anti-VEGFR2 blocking antibody (DC101) purified in our 125 
laboratory or 3) ChromPure Mouse IgG1 whole molecule as isotype control (Jackson 126 
Immuno Research Laboratories, Inc). All dosed at 1mg/animal once a week IP except 127 
for anti-VEGFR2 which was administered twice-a-week as previously described (21).  128 
Histological analyses and quantification 129 
Frozen or paraffin samples of Pancreata and livers were histologically evaluated with 130 
primary antibodies: anti-CD31 (550274; 1:50; BD Biosciences); anti-T-antigen 131 
(1:10000; Hanahan laboratory), anti-Hypoxyprobe (1:50; NPI Inc), anti-GLUT1 (ab652; 132 
1:100; Abcam), anti-Type IV Collagen (AB756P; 1:200; Millipore), anti-Lyve1 (103-133 
PA50AG; 1:100; ReliaTech), anti-Desmin (ab15200; 1:150; Abcam), anti-NG2 134 
(AB5320; 1:50; Millipore), anti-SMA-Cy3 (C6198; 1:200; Sigma-Aldrich), anti-SMA (RB-135 
9010; 1:100; Thermo Scientific), anti-PlxnB1 (sc-28372; 1:50; Santa Cruz 136 
Biotechnology), anti-Sema4D (G3256; 2 µg/mL; Vaccinex company), anti-F4/80 137 
(MCA497R; 1:50; AbD Serotec), anti-CD3e (550275; 1:10; BD Bioscience), anti-CD72 138 
(PAB261Mu01; 1:100; Cloud-clone Corp), anti-SDF1 (MAB350, 1:20, R&B System), 139 
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anti-CXCR4 (C8352, 1:750, Sigma), and anti-Insulin (A0564; 1:50; Dako). Microvessel 140 
density, pericyte coverage of tumor vessels, macrophage infiltration, CXCR4, SDF1 141 
and Sema4D expression were manually quantified per field. Collagen IV, VE-cadherin 142 
and tumor hypoxia were measured as the mean positive area per field. 143 
Cell culture and conditioned media obtention 144 
βTC4 cell line was isolated from RIP1-Tag2 tumors in Hanahan laboratory and grown 145 
in DMEM 20% FBS. To discard undifferentiation events, they were not used beyond 50 146 
passages and their phenotype was authenticated by insulin expression by 147 
immunocytofluorescence. RAW264.7 cell line, donated by E. Ballestar (IDIBELL), was 148 
grown in DMEM 10% FBS and THP-1 cells, donated by I. Fabregat (IDIBELL), were 149 
grown in RPMI 10% FBS. These had been bought by ATCC and authenticated by STR 150 
profiling by the ATCC. HUVEC cells from CellTech (Spain) were grown in EGM/EBM2 151 
10% iFBS. All cell lines were examined for mycoplasma contamination using PCR 152 
analysis every month. For conditioned media: RAW264.7, HUVEC and THP-1 cells 153 
were grown in free-serum DMEM and treated with anti-Sema4D (10 µg/mL), either 154 
Vaccinex (Mab67) or Abnova (3B4), isotype-specific anti-IgG1 (10 µg/mL, isotype 155 
control), or without treatment (control) during 24h. RAW264.7 cells were also treated 156 
with recombinant Sema4D (5235-S4-050 and PlxnB2 (6836-PB-050) at 1 µg/mL (R&D 157 
systems). In added conditioned media the antibodies were added after media 158 
collection.  159 
Generation of shRNA RAW264.7 clones 160 
shRNAs designed by The RNAi Consortium (TRC) cloned into the pLKO.1 lentiviral 161 
vector were purchased from Dharmacon (GE Healthcare) for silencing of Sema4D 162 
(TRCN0000067493), CD72 (TRCN0000066042), Plxnb2 (TRCN0000078853) and non-163 
targeting shRNA (shNS) as a negative control. shRNA lentivirus were used to 164 
transduce RAW264.7 cells with 8 µg/ml polybrene and after 48h selected with 1 μg/mL 165 
puromycin for 5 days. 166 
Migration and matrigel invasion transwell assays 167 
Corning migration and invasion assays (#3422 & #354480) were performed following 168 
manufacturer’s instructions. RAW264.7 and THP-1 cells were treated with anti-169 
Sema4D (10 µg/mL), either Vaccinex (Mab 67) or Abnova (3B4), isotype-specific IgG1 170 
(10 µg/mL) or without treatment.  βTC4 cells in serum-free DMEM media were 171 
subjected to RAW264.7 conditioned media. For chemotaxis assay for SDF1, 172 
treatments included 1 μg/ml AMD3100 (3299, Tocris) and 100 ng/ml recombinant 173 
SDF1 (250-20A, Peprotech).  174 
Protein analysis and RNA Analysis 175 
Tumor samples and βTC4 and RAW264.7 cell lysates were analyzed by WB with: c-176 
met (sc-8057; 1:100; Santa Cruz Biotech.), phospho-c-met (3077; 1:750; Cell 177 
Signaling), PlxnB2 (AF5329; 1:1000; R&D), Sema4D (MAB5235; 1:250; Novus 178 
Biologicals), CD72 (AF1279; 1:500; R&D), α-tubulin (32-2500; 1:2000; Invitrogen). For 179 
mRNA, RNA extraction and High-Capacity RT reaction (Applied Biosystems) produced 180 
cDNA for RT-PCR using LDA Arrays for 24 genes (Supplementary Table 1) and SDF1 181 
and CXCR4, HPRT1 (mouse and human), and cMET and β-ACTIN (mouse) Taqman 182 
probes (Applied Biosystems). 183 
Cytokine Array and ELISA 184 
Supernatants of RAW264.7 conditioned media were analyzed by mouse cytokine 185 
antibody array (#AAM-CYT-1000; RayBiotech, Inc.) according to the manufacturer’s 186 
instructions. Mouse SDF1 ELISA (MCX120, R&D) was performed after concentrating 187 
supernatants with Vivaspin 2 KDa column (Sartorius). Similarly, human SDF1 ELISA 188 
(DSA00; R&D) was done in supernatants of HUVEC and THP-1 conditioned media. 189 
Mouse Omics and Clinical data analysis 190 
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Gene expression data from different stages of RIP1-Tag2 mice (GEO Omnibus ID – 191 
GSE73514) and human mRNA transcriptomes from a core independent clinical gene 192 
expression dataset of PanNET (GEO Omnibus ID – GSE73338) patients were used 193 
(22,23). For RIP1-Tag2 mice data, primary tumors (n=5) and metastases (n=3) 194 
samples were compared. For the human study, normal pancreatic islet samples (n=4), 195 
nonfunctional samples (n=63), which were termed primary tumors, and their 196 
corresponding metastases (n=7) were evaluated. To further study the malignization 197 
process, primary tumors were divided into two subcategories, non-malignant and 198 
malignant, according to the clinical history of the patients (23).  199 
Statistical Analysis 200 
Results are presented as mean + SD, except for transwell assays, which results are 201 
presented as mean + SEM. The statistical tests are noted in each figure and 202 





Treatment with anti-Sema4D exerts an antitumor and prosurvival effect 208 
Initially, the presence of Sema4D and its high affinity receptor PlxnB1 was evaluated. 209 
Sema4D was found to be highly expressed in the membrane of scattered single cells 210 
inside tumor parenchyma with a pattern compatible with immune cells and weakly 211 
expressed in the membrane of tumor cells (Supplementary Figure 1A), consistent with 212 
previous reports (15,17). PlxnB1 was immunodetected in a 30% of vascular structures 213 
(Supplementary Figure 1B). To assess the effects of anti-Sema4D treatment, we used 214 
a specific antibody (anti-Sema4D, Mab67 Vaccinex) (20) in RIP1-Tag2 mice and 215 
focused on tumor growth and expansion phase of islet carcinoma. Therapeutical 216 
regimes included 2 or 4 weeks anti-Sema4D treatment along with treatment with 217 
DC101, a well described blocking monoclonal antibody of VEGFR2 (21). We could 218 
determine that 4 weeks therapy produced an inhibition in tumor growth similar to the 219 
one observed after anti-VEGFR2 (α-VR2) treatment (Figure 1A), which promoted an 220 
extension of lifespan of treated mice (Figure 1B). These results suggest an anti-tumor 221 
benefit of anti-Sema4D therapy in terms of tumor shrinkage and lifespan increase in 222 
mice. 223 
 224 
Altered vessel structure and functionality 225 
A qPCR for angiogenesis related genes such as angiopoietins and platelet-derived 226 
growth factor receptors was modified after the treatment (Supplementary Table 1). 227 
Suprisingly, in contrast to differences observed after anti-VEGFR2, treatment with anti-228 
Sema4D did not show any differences in number of vessel structures (Figure 1C; 229 
Supplementary Figure 1C top) or CD31 area density (Figure 1D) nor matrix deposition 230 
of endothelial cells determined using type IV collagen (Figure 1E; Supplementary 231 
Figure 1C middle). Moreover, there was no difference in area and structure of 232 
endothelial cell-cell junctions, as shown by VE-cadherin evaluation (Figure 1F, 233 
Supplementary Figure 1C bottom), in contrast to the significant alterations observed 234 
after anti-VEGFR2 therapy. Other vascular parameters such as number of branches 235 
and empty sleeves did not show any differences either (Supplementary Figure 1D-E). 236 
Lymphangiogenesis was also evaluated, observing no lymphangiogenic events neither 237 
in the control nor in the anti-Sema4D treated condition (Supplementary Figure 2A). 238 
   6 
 
Together, these data indicate that anti-Sema4D treatment does not produce a classical 239 
anti-angiogenic effect at the endothelial level on RIP1-Tag2 model. To mechanistically 240 
understand why anti-Sema4D does not exert a direct anti-angiogenic effect, we 241 
evaluated the presence of membrane-bound or soluble Sema4D forms in our model. 242 
As shown in Supplementary Figure 2B, in RIP-Tag2 tumors we can only detect 243 
Sema4D transmembrane full-length form (150 KDa) and not detect any soluble form 244 
(110-115 KDa). As the soluble form has been associated to angiogenesis, the lack of 245 
this soluble form is consistent with a lack of antiangiogenic effects of anti-Sema4D. 246 
 247 
Since many other cellular types such as pericytes play fundamental structural and 248 
functional roles in blood vessels, pericyte coverage was evaluated to determine 249 
whether they were subjected to a further structural change after anti-Sema4D therapy. 250 
Pericytes positive for Desmin and NG2 were increased after anti-Sema4D treatment 251 
whereas the number of α-SMA positive pericytes was decreased (Figure 1G; 252 
Supplementary Figure 3A). This alteration in pericyte profile suggests a switch to a 253 
more immature vessel type associated to vascular remodeling. In addition, after anti-254 
Sema4D therapy there is a nearly two-fold increase in the number of PlxnB1 positive 255 
structures (Supplementary Figure 3B). Next, we checked whether these changes in 256 
pericyte coverage occur in PlxnB1 possitive vessels (Supplementary Figure 3C). No 257 
difference in pericyte coverage between the PlxnB1 positive or negative endothelial 258 
cells was observed, evidencing that pericyte coverage is independent from the 259 
expression of PlxnB1 in endothelial cells. This suggests an indirect crosstalk between 260 
endothelial cells and pericytes. 261 
 262 
Based on previous work (24), where Sema4D treatment of endothelial cells elicits 263 
production of PDGF-BB and promotes differentiation of mesenchymal stem cells into 264 
pericytes, thus producing pericyte proliferation, chemotaxis, and association with 265 
HUVECs in a capillary network, we checked PDGF-BB expression. ELISA assay of 266 
PDGF-BB showed a slight decrease in PDGF-BB levels in α-Sema4D treated tumors 267 
when compared to control tumors (Supplementary Figure 4). This result was 268 
concordant with our RNA analysis in which a decrease in PDGF-BB levels was also 269 
observed (Supplementary Table 1).  270 
 271 
To assess if altered pericyte coverage after anti-Sema4D had further consequences in 272 
vascular functionality, we checked vascular integrity. We evaluated a vascular leakage 273 
parameter such as extravassation of erithrocytes (microhemorrhaging) in the form of 274 
tumor hemorrhagic phenotype. The percentage of hemorrhagic tumors after 2 weeks of 275 
anti-Sema4D therapy was significantly reduced when compared to control animals, 276 
although this reduction was even stronger with anti-VEGFR2 treatment (Figure 1H; 277 
Supplementary Figure 5A left). These effects were maintained in long term treatment 278 
(Supplementary Figure 5A right). Aiming at identifying other possible causes of the 279 
change in pericyte coverage after anti-Sema4D treatment, we screened for CD72 low 280 
affinity receptor presence in pericytes from tumor vasculature. We could determine that 281 
CD72 is not expressed in vascular nor perivascular cells (Supplementary Figure 5B). 282 
CD72 was rather found to be expressed in single cells, suggestive of its expression in 283 
cells of the immune system infiltrated in tumor stroma (Supplementary Figure 5C). This 284 
result is further confirmed by a double costaining of CD72 and F4/80 positive 285 
macrophages (Supplementary Figure 5D). 286 
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 287 
Increased invasiveness and metastasis after anti-Semaphorin 4D treatment  288 
Anti-Sema4D treatment increases the number of highly invasive tumors progressively, 289 
similar to the effect of anti-VEGFR2 (Figure 2A and B). While the majority of control 290 
tumors were predominantly encapsulated or microinvasive, treated tumors presented 291 
wide fronts of invasion encroaching into adjacent acinar tissue. Significantly, this effect 292 
was further exacerbated when anti-Sema4D therapy was maintained for 4 continuous 293 
weeks (Figure 2B). Study of livers and peripancreatic lymph nodes (LN) revealed that 294 
anti-Sema4D treated mice more frequently contained enlarged LN containing tumor 295 
cells and distant metastasis to the liver (Figure 2C). The incidence of LN metastasis 296 
grew from the 30% in untreated controls to more than 70% in treated groups, indicating 297 
that similarly to what happens with VEGFR2 inhibition, anti-Sema4D treatment 298 
promotes an increase in LN metastasis (Figure 2D, left). Incidence of liver metastasis 299 
was 2-fold higher in those mice that had received an antiangiogenic treatment, either 300 
anti-VEGFR2 or anti-Sema4D (Figure 2D, right). When combining anti-Sema4D and 301 
anti-VEGFR2, results in tumor burden, survival, invasiveness and metastases 302 
incidence were identical as in anti-VEGFR2 alone (Supplementary Figure 6). This lack 303 
of additional effectof anti-Sema4D evidences the predominant role of VEGF in 304 
triggering angiogenesis over Sema4D in this tumor setting.   305 
 306 
Overall, the data presented here demonstrate that anti-Sema4D treatment promotes 307 
the acquisition of an adaptive resistance, with similar effects of the complete and 308 
lasting inhibition of angiogenesis caused by the use of anti-VEGFR2 or TK inhibitors as 309 
sunitinib and sorafenib (19,25).  310 
 311 
Malignization after anti-Sema4D treatment is not produced by known 312 
mechanisms 313 
Treatments targeting tumor vasculature are described to produce an increase in 314 
hypoxia as a consequence of the antiangiogenic effect. Surprisingly, anti-Sema4D 315 
treatment did not induce hypoxia in short-term treated tumors, as demonstrated by the 316 
presence of pimonidazole adducts or by the increase in the expression of hypoxia-317 
response genes such as Glut1 (Figure 3A) in anti-VEGFR2 treated tumors. 318 
Quantification of this event at longer treatment regimes confirmed this observation 319 
(Figure 3B-C). Taken together, these data suggest that a hypoxia independent pathway 320 
is responsible for the increase in invasion and malignization. 321 
 322 
Up to now, the best described mechanism of tumor aggressiveness after anti-vascular 323 
inhibition in RIP1-Tag2 tumors involves hypoxia and c-met activation (26,27). RNA 324 
analysis of untreated and anti-Sema4D treated tumors revealed that there were no 325 
changes in c-met expression (Figure 3D). We then assayed the presence of its 326 
precursor protein and its active form, phosphorylated c-met, by western blotting, using 327 
HGF (c-met natural ligand) to stimulate cells. No expression of the precursor and any 328 
activation of c-met signaling pathway was observed, neither in the untreated nor in the 329 
anti-Sema4D treated conditions (Figure 3E). Similarly, even if βTC4 cells express c-330 
met at low transcriptional levels, there is no pathway activation in response to anti-331 
Sema4D or HGF (Figure 3F-G). Overall, these data suggest that malignization effects 332 
in RIP1-Tag2 mice are restricted to an indirect effect of Sema4D over tumor cells, 333 
rather than to a direct action of the pro-angiogenic molecule upon tumor cell derived c-334 
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met. Moreover, a retrograde effect of Sema4D over tumor cells was discarded since no 335 
changes in cell adhesion, de-adhesion or proliferation of RIP1-Tag2-derived βTC4 336 
tumor cells were observed (Supplementary Figure 7). 337 
 338 
Anti-Sema4D treatment produces an increase in tumor-associated macrophage 339 
(TAM) migration 340 
Among all immune cells expressing Sema4D (28–31), a relevant role in pro-341 
tumorigenic processes has been specifically described for lymphocytes and TAMs 342 
(13,14). CD3e-positive T-lymphocytes infiltrated in the RIP-Tag2 tumor parenchyma 343 
were very scarce and, while anti-Sema4D treatment produced an increase in their 344 
numbers, the absolute amount was too low to consider them functionally relevant 345 
(Supplementary Figure 8). On the other hand, a co-staining of macrophage marker 346 
F4/80 with Sema4D in our tumors showed that most macrophages did not express 347 
Sema4D, few expressed it with high intensity and some only in certain areas of the cell 348 
(Figure 4A). However, we found a visible higher amount of Sema4D positive 349 
macrophages after anti-Sema4D therapy (Figure 4A) and the total number of 350 
macrophages was significantly increased (Figure 4B). In fact, while the number of 351 
Sema4D negative macrophages was maintained invariable after the therapy (Figure 352 
4C), the number and percent of Sema4D positive macrophages increased after short 353 
term anti-Sema4D treatment (Figure 4D). In conjuction, these data demonstrated that, 354 
in vivo, there was a change in the number and phenotype of TAMs after anti-Sema4D 355 
treatment. In order to functionally validate its consequences, the migration properties of 356 
a Sema4D-expressing murine macrophage cell line, RAW264.7 (Supplementary Figure 357 
9A), were evaluated after anti-Sema4D treatment. As shown in Figure 4E, there was an 358 
increase in migration of RAW264.7 cells after anti-Sema4D therapy, which occurred in 359 
a dose dependent manner (Supplementary Figure 9B). Moreover, the addition of 360 
exogenous recombinant Sema4D did not reduce basal macrophage migration, 361 
indicating the requirement for Sema4D expression in cell membrane for the antibody to 362 
have an effect (Figure 4E). To decipher the underlying mechanism, effective 363 
knockdowns of the ligand Sema4D and its two receptors expressed in RAW264.7 cells, 364 
CD72 and PlxnB2 were generated (Supplementary Figure 9C). Interestingly, we 365 
observed that there was no change in migratory capacity of RAW264.7 cells in any of 366 
the gene knockdowns (Figure 4F). Moreover, anti-Sema4D treatment continued to 367 
produce the same increase of migration in all gene silencing conditions except for 368 
shSema4D cells (Figure 4G; Supplementary Figure 9D). Altogether, our results define 369 
a receptor-independent and Sema4D-requirement for antibody induction of migration 370 
and they demonstrate that Sema4D needs to be expressed in the membrane of the 371 
cells for the antibody to have an effect. Thus, all these data define an antibody-induced 372 
retrograde signaling engagement of Sema4D which has already been previously 373 
published for this family of transmembrane proteins in different settings (reviewed in 32 374 
and 33). 375 
 376 
Most macrophage activity is mediated by cytokines and chemokines that act in 377 
autocrine fashion and paracrine fashion, upon other macrophages or even upon other 378 
cells from the tumor ecosystem. Aiming to delve into macrophage study, we performed 379 
a mass spectrometric analysis (LC-MS/MS) of secreted proteins (secretome) 380 
composing RAW264.7 conditioned media previously stimulated with anti-Sema4D. The 381 
proteomic approach resulted in the identification of more than a thousand proteins 382 
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(Supplementary Table 2). Using Gene Set Enrichment Analysis (GSEA) bioinformatics 383 
tool, we showed a statistical enrichment in proteins related to important macrophage 384 
functions: cell migration, cell projection, cytoskeleton and RAC1 pathway (grouped in 385 
migration); DNA replication and cell cycle (grouped in proliferation); FCγR mediated 386 
phagocytosis and immunological synapse (grouped in activation) (Supplementary 387 
Figure 10). Taken together, the analysis of the secretome by proteomic profiling 388 
suggests a direct effect of Sema4D upon macrophage activity, specially affecting their 389 
migration, proliferation and activation. 390 
 391 
Tumor-associated macrophages are promoting invasion in βTC4 cells as a 392 
response to anti-Sema4D treatment 393 
To check the behaviour of TAMs in tumor periphery, the number of macrophages in the 394 
perimeter of the base protrusions of invasive fronts was determined after co-staining 395 
Sema4D with F4/80 macrophage marker and the RIP1-Tag2 tumor cell marker insulin 396 
(Figure 5A). Contrary to the intratumoral results, the number of macrophages in the 397 
invasive fronts remained unaltered after anti-Sema4D treatment (Figure 5B). The 398 
number of peritumoral Sema4D negative macrophages decreased, while the number of 399 
Sema4D positive macrophages and their percentage are strongly increased after 400 
treatment (Figure 5D). The abrupt change in macrophage number and phenotype may 401 
indicate a role for these cells in the invasive and malignization process that occurs after 402 
the therapy. 403 
 404 
To confirm this hypothesis, an in vitro matrigel invasion assay using βTC4 cells was 405 
performed. The addition of conditioned medium of RAW264.7 cell line treated with anti-406 
Sema4D significantly increased the invasive properties of βTC4 cells (Figure 5E). 407 
Nevertheless, conditioned media from neither Sema4D, CD72 nor PlxnB2 knockdown 408 
RAW264.7 cells did not recapitulate this tumor cell invasion increase (Figure 5F). On 409 
the other hand, conditioned media of anti-Sema4D treated shSema4D RAW264.7 cells 410 
did not induce an increase, but rather a decrease of tumor cell invasion 411 
(Supplementary Figure 11). Therefore, Sema4D retrograde signaling engagement by 412 
anti-Sema4D produces a switch of the macrophage phenotype that potentiates tumor 413 
cell invasion in RIP1-Tag2, probably by promoting secretion of a pro-invasive molecule.  414 
 415 
SDF1/CXCL12 is responsible for promoting invasion as a response to anti-416 
Sema4D treatment 417 
In pursuance of identifying the pro-invasive molecule secreted by macrophages and 418 
responsible for tumor cell invasion after anti-Sema4D therapy, a mouse cytokine array 419 
was performed in supernatants of RAW264.7 conditioned media. Even though not 420 
many significant changes were observed between different treatment conditions 421 
(Supplementary table 3), a statistically significant increase in stromal cell-derived factor 422 
1 (SDF1, also known as CXCL12) molecule was detected in anti-Sema4D treated 423 
supernatant (Figure 6A). An ELISA analysis of secreted SDF1 revealed an increase in 424 
anti-Sema4D condition which was not observed neither in control or treated Sema4D 425 
knockdown macrophages (Figure 6B), nor in cells treated with recombinant PlxnB2 426 
(Supplementary Figure 12A) or receptor-knockdown cells (Supplementary Figure 12). 427 
We validated SDF1 as a possible macrophage secreted candidate responsible for 428 
cancer cell invasion in the RIP1-Tag2 model by an invasion assay in the in vitro setting. 429 
As expected, βTC4 cells responded to recombinant SDF1 stimulation in vitro by 430 
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increasing their invasion (Figure 6C). This phenomenon was inhibited when CXCR4 431 
receptor was blocked by its antagonist AMD3100. In addition, the increase observed in 432 
βTC4 cells’ invasion after anti-Sema4D treated conditioned media addition is 433 
comparable to the one produced when exogenous SDF1 was added to IgG1 treated 434 
conditioned medium (Figure 6D). Consistently, when AMD3100 was added to anti-435 
Sema4D treated conditioned medium, the invasive capability of βTC4 cells dropped to 436 
basal levels, confirming that SDF1 is one of the factors secreted by macrophages after 437 
anti-Sema4D treatment responsible for tumor cell invasion. 438 
 439 
Finally, we sought to check whether in RIP1-Tag2 model the SDF1/CXCR4 signaling 440 
axis was present and affected by anti-Sema4D treatment. We found an increased trend 441 
of both CXCR4 and SDF1 RNA expression in treated tumors (Supplementary Figure 442 
12C-D), that was further confirmed by immunohistochemistry (Figure 6E-F). CXCR4 443 
receptor appears to be expressed homogeneusly by RIP1-Tag2 tumor cells, albeit at 444 
low levels in control samples and highly present in anti-Sema4D treated mice (Figure 445 
6E), possibly due to an SDF1-induced positive feed-forward mechanism (34). Indeed, 446 
CXCR4 is naturally present in the tumor progression stages of RIP1-Tag2 mice, 447 
showing expression in metastases, both in control and anti-Sema4D treated mice 448 
(Supplementary Figure 12E-F). Therefore, anti-Sema4D treatment seems to 449 
exacerbate an already existing CXCR4-mediated metastasis mechanism. As expected, 450 
SDF1 was found both in cells with a vascular phenotype and also in round shaped cells 451 
compatible with immune infiltrates. The count of the latter showed an increase in SDF1 452 
positive round cells after the treatment (Figure 6F). A costaining of both Sema4D and 453 
SDF1 showed an enrichment in SDF1/Sema4D double positive cells after the treatment 454 
(Supplementary Figure 12G and Figure 6G). Since endothelial cells also express 455 
SDF1, we analyzed the behavior of HUVEC cells in response to anti-Sema4D, 456 
observing no changes in gene expression but an increase in SDF1 release after the 457 
treatment (Supplementary Figure 13).  458 
 459 
Altogether, the in vivo results may suggest a tumor-independent origin of SDF1 that 460 
could bind to its receptor in RIP1-Tag2 tumor cells to exert its activity. Furthermore, a 461 
deeper analysis associating SDF1 levels and invasive capacity of the tumor front 462 
revealed a relationship between the invasive capacity and ligand concentration in 463 
control tumors (Figure 6H). This relationship was slightly lost after anti-Sema4D 464 
treatment.  465 
 466 
Clinical relevance of Sema4D and SDF1/CXCR4 axis 467 
After demonstrating both in vitro and in vivo the role of Sema4D and SDF1/CXCR4 in 468 
tumor malignization of the RIP1Tag2 mouse model, we sought to decipher whether 469 
these same mechanisms could be also playing the role in the clinical setting. We found 470 
Sema4D expression to be significantly increased in metastatic samples when 471 
compared to either primary non-malignant and malignant tumors or normal pancreatic 472 
controls (Figure 7A). Besides, whereas SDF1 expression remained practically 473 
unaltered, we found a significant increase in CXCR4 receptor expression between 474 
normal and both primary tumor subtypes and metastases (Figure 7B-C). In fact, there 475 
is a gradual increase of CXCR4 that correlates with malignization, thus implying a role 476 
for this protein as a tumor progression driver. Furthermore, we evaluated the 477 
correlation between Sema4D and CXCR4 expression in non-malignant (non-478 
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metastatic) and malignant (metastatic) primary tumor samples of PanNET patients. 479 
Contrary to non-metastatic patients, malignant patients showed higher levels of CXCR4 480 
that showed a correlation with Sema4D (Figure 7D). We finally validated our results 481 
using the human macrophage cell line, THP-1 (Figure 7E-F). After anti-Sema4D 482 
treatment, THP-1 cells demonstrated an increased migratory phenotype and SDF1 483 
release (Figure 7E-F), without alteration of CXCL12 or CXCR4 expression 484 
(Supplementary Figure 14). Overall, the clincal data validates a possible link of 485 





Compared to the canonical VEGF, Sema4D is a molecule with quite a different role in 491 
angiogenesis since its binding to PlxnB1 can promote different and sometimes 492 
opposing cellular responses including vascular guidance (35). Indeed, these 493 
differences in vascular targeting potential provide an explanation for the negligible 494 
effects in endothelial structures after anti-Sema4D treatment without reduction in MVD 495 
and no increased levels of tumor hypoxia. Nevertheless, by PDGF-B reduction anti-496 
Sema4D treatment produced a pericyte structural alteration that functionally modified 497 
vessel perfusion and hyperpermeability, thus altering tumor growth. 498 
Moreover, it is widely accepted that a partial inhibition of angiogenesis would not 499 
produce an increase of hypoxia within tumours and could not trigger the secondary 500 
unwanted pro-invasive and malignant effects (27). Contrarily, we have observed that 501 
although anti-Sema4D therapy produced a partial effect in vessel functionality, without 502 
induction of hypoxia, it still produced the same pro-invasive effect as anti-VEGF 503 
therapy in the PanNET model. 504 
 505 
Anti-Sema4D promotes tumor invasion via Tumor-associated macrophages 506 
Protumoral roles for Sema4D typically involve tumor cell-derived Sema4D and there is 507 
little evidence about the role of stromal Sema4D (36), Interestingly, in RIP1-Tag2 508 
tumors, the main source of Sema4D are macrophages infiltrating the tumor stroma. In 509 
recent years, a critical role for tumor microenvironment and particularly TAMs has been 510 
demonstrated (37,38). Their contribution to tumor growth and progression has even 511 
been reported in the clinical setting, with correlation between a high intratumor TAM 512 
content and a poor prognosis (38). In this study we observe an increase in SEMA4D 513 
positive macrophages inside tumors and in the invasive front, which goes in agreement 514 
with previously published data where Sema4D controls immune cell motility (10)(39). 515 
Our knockdown and recombinant Sema4D experiments strongly suggest that the 516 
antibody mediates a Sema4D-dependent retrograde signaling engagement in the 517 
membrane of macrophages, rather than a function blocking effect. This retrograde 518 
signaling has been previously published for this family of transmembrane proteins in 519 
different settings (reviewed in 32 and 33). Furthermore, we validated these results 520 
utilizing another anti-Sema4D antibody clone 3B4, but not with clone SK-3, which 521 
demonstrates these are antibody-specific effects over macrophages. 522 
 523 
SDF1/CXCR4 signaling axis has an important role in cancer progression (40). In vitro, 524 
we have proven the chemoattractant capacity of SDF1 and its stromal origin, and we 525 
have demonstrated that SDF1 release from macrophages is dependent on Sema4D 526 
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expression and independent of its receptors. In vivo, our results show tumor cells ability 527 
to respond to SDF1 stimulus, both in primary tumors and metastases, and the 528 
existence of a receptor-ligand positive feedback loop. In fact, the correlation between 529 
the invasive capacity of the tumor and SDF1 concentration in control tumors, which is 530 
lost after anti-Sema4D treatment, suggests that the SDF1/CXCR4 signaling cascade is 531 
already activated regardless of the invasive capacity of the treated tumors.  532 
 533 
In the clinical setting, VX15/2503, the humanized anti-Sema4D antibody, showed 534 
promising results in the first-in-human phase I clinical trial, with a 45% of patients 535 
exhibiting the absence of disease progression for at least 8 weeks (17). Consistently, 536 
our own data show anti-Sema4D antibody inhibits tumour growth of PanNETs with a 537 
tendency to increase lifespan but also invasion and metastasis. This latter adaptive 538 
response to treatment has not been evaluated in patients. Importantly, the combined 539 
expression of Sema4D and PlxnB1 is an independent risk factor for disease relapse in 540 
colorectal cancer. (41). Other tumors where Sema4D overexpression has been 541 
reported as a negative prognostic marker include breast, ovary, soft tissue sarcomas 542 
and pancreas (42–44). Our data demonstrate that both Sema4D and CXCR4 543 
expression increase with tumor progression in PanNETs and also a positive correlation 544 
between Sema4D and CXCR4 expression in metastatic PanNET samples. Thus 545 
implying that Sema4D and CXCR4 expression are related to the malignization process 546 
in patients. Taking into account the inexistence of anti-Sema4D treated PanNET 547 
patient samples, these study remarks the role of Sema4D as a potential candidate of 548 
tumor malignization in this type of tumors. We have proven, using in vitro, in vivo and in 549 
silico approaches, that stromal or immune cells are the primary source of Sema4D, 550 
rather than tumor cells.  551 
 552 
In conclusion, we describe a hypoxia independent novel mechanism of tumor 553 
malignization in the RIP1-Tag2 model, where the signaling engagement of anti-554 
Sema4D antibody binding to Sema4D in macrophages seems to be responsible for the 555 
malignant phenotype via SDF1/CXCR4 signaling axis activation (Figure 7G). Our study 556 
suggests a combinantion of anti-Sema4D therapy and small molecule inhibitors of 557 
selected macrophage functions coud be a new therapeutical strategy for PanNET 558 
patients. Future studies combining non-traditional anti-angiogenics and novel 559 
immunotherapies would undoubtedly shed light into the role of tumor-associated cells, 560 
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 746 
FIGURE LEGENDS 747 
 748 
Figure 1. Anti-Sema4D treatment demonstrates anti-tumor effects and extends 749 
survival by vascular targeting. A) Quantification of tumor volume of untreated (Ctrl), 750 
anti-Sema4D (α-S4D) and anti-VEGFR2 (α-VR2) treated for 4 wks (n≥10). B) Kaplan-751 
Meier survival curves. Log rank test 0.0027 (n≥20). C,E) Quantification of the number 752 
of vessel structures (MVD) by CD31 staining and the CD31 area density (%) per field of 753 
viable tumor. D,F,G) The percentage of the area of type IV collagen, vascular cadherin 754 
(VE-cadherin) or the vascular structures covered by different pericyte markers 755 
(Desmin, NG2 and α-SMA) per field of viable tumor normalized by the total number of 756 
vessel structures. H) Quantification of the percentatge of tumors with vessel 757 
microhemorraging. C-H. All treatments were performed during 4 weeks. Mann-Whitney 758 
test (n≥10 except for pericyte coverage, n≥5). 759 
 760 
Figure 2. Therapy-induced local invasiveness and distant metastasis. A) H&E 761 
staining of tumors of untreated (ctrl), anti-Sema4D (α-S4D) and anti-VEGFR2 (α-VR2) 762 
treated animals for 2 wks. B)  Quantification of tumor invasiveness of encapsulated, 763 
microinvasive and highly invasive tumors per animal after short (2 wks, left) and long (4 764 
wks, right) treatment with anti-Sema4D and anti-VEGFR2. Fisher exact probability test 765 
(n≥5). C left) Enlarged lymph node after 4-weeks anti-Sema4D treatment (first picture). 766 
The presence of tumor cells inside the lymph node is corroborated with T antigen 767 
staining (second picture). C right) H&E of micrometastasis in liver after 4-weeks anti-768 
Sema4D therapy (third picture) and its respective T antigen staining corroboration 769 
(forth picture). D) Incidence of lymph node metastasis (left) and liver micrometastasis 770 
(right) after the anti-Sema4D or the anti-VEGFR2 treatment for 4 weeks compared to 771 
untreated control animals. Chi-square test (n≥10). E) Quantification of the number of 772 
liver metastatic lesions in control, anti-Sema4D and anti-VEGFR2 treated animals after 773 
4 weeks of treatment. Mann-Whitney test (n=4). 774 
 775 
Figure 3. Anti-Sema4D treatment-related malignization does not produce 776 
intratumor hypoxia and neither alters c-Met expression nor its activation. A) 777 
Immunohistochemistry staining for Glut1 and pimonidazole (pimo) in untreated (ctrl), 778 
anti-Sema4D (α-S4D) and anti-VEGFR2 (α-V2R) treated samples. B) Quantification of 779 
the incidence of hypoxic tumors after anti-Sema4D and anti-VEGFR2 1 week treatment 780 
compared to controls by staining of pimonidazole adducts (n≥132). C) Quantification by 781 
Glut1 staining of the incidence of hypoxic tumors in anti-Sema4D and anti-VEGFR2 2 782 
wks short-term (left) and 4 wks long-term (right) treatments compared to controls 783 
(n≥75). B-C. Mann-Whitney test. D) qRT-PCR Taqman analysis of c-met relative to 784 
Hprt1 housekeeping gene expression. RNA from RIP1-Tag2 untreated or anti-Sema4D 785 
treated mice was analyzed. Mann-Whitney test (n=3). E) Western blot analysis of the 786 
active form of c-Met protein (phospho c-met) in control and α-S4D treated RIP1-Tag2 787 
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tumors. α-tubulin protein is used as a housekeeping control. Lysate from A549 cells 788 
treated with HGF in equal conditions was used as a positive control for c-met 789 
phosphorylation. RAW cell line was used as a negative control. F) qRT-PCR Taqman 790 
analysis of c-met relative to Hprt1 housekeeping gene expression. RNA from  βTC4 791 
cells was analysed and RNA from murine kidney tissue was used as a positive control. 792 
G) Western blot analysis of the active form of c-Met protein (phospho c-met) in two 793 
independent samples of control, anti-Sema4D (α-S4D) and HGF treated βTC4 cells. α-794 
tubulin protein is used as a housekeeping control. Lysate from A549 cells treated with 795 
HGF in equal conditions was used as a positive control for c-met phosphorylation. 796 
RAW cell line was used as a negative control. 797 
 798 
Figure 4. Tumor-associated macrophages respond to anti-Sema4D treatment 799 
increasing their migration. A) Double immunofluorescence of Sema4D and F4/80 in 800 
IgG1 and anti-Sema4D (α-S4D) treated samples (2 wks treatment). White arrows 801 
reveal the expression of Sema4D by some TAMs. B-D) Quantification of the number of 802 
intratumoral total TAMs, Sema4D negative TAMs or Sema4D positive TAMs per field 803 
and the percentage of intratumoral Sema4D positive TAMs per total number of TAMs. 804 
IgG1 treated mice were used as a control. Mann-Whitney test (n≥20). E) Quantification 805 
of the number of migrated RAW 264 cells per field in untreated, IgG1, anti-Sema4D 806 
and recombinant Sema4D (rS4D) treatment conditions. Results are presented as 807 
number of migrated cells per field  normalized by the untreated control. Mann-Whitney 808 
test (n≥45). F) Quantification of the number of migrated RAW 264 cells per field in 809 
parental and sh Sema4D, sh CD72, sh PlexinB2 and sh NS RAW 264 cells. Results 810 
are presented as number of migrated cells per field  normalized by the parental control. 811 
Mann-Whitney test (n≥30). G) Quantification of the number of migrated RAW 264 cells 812 
per field in untreated and anti-Sema4D treatment conditions in sh Sema4D ans sh NS 813 
(non-silencing control) RAW 264 cells. Mann-Whitney test (n≥45). 814 
 815 
Figure 5. Increase in the number of peritumoral Sema4D positive macrophages in 816 
the tumor invasive fronts and response to anti-Sema4D therapy by increasing 817 
βTC4 invasion potential. A) Triple immunofluorescence co-staining for Insulin, F4/80 818 
and Sema4D in tumor fronts of IgG1 and anti-Sema4D treated animals. B-D) 819 
Quantification of the number of peritumoral total TAMs, Sema4D negative TAMs or 820 
Sema4D positive TAMS  normalized by the perimeter of the base tumor protrusions 821 
(µm) in the invasive fronts and the percentage of Sema4D positive TAMs per total of 822 
TAMs.  Mann-Whitney test (n≥20). IgG1 treated mice were used as a control. E) 823 
Quantification of invasive βTC4 cells per field in the presence of the conditioned media 824 
of untreated, IgG1 added or treated and anti-Sema4D added or treated RAW 264 cells 825 
used as chemoattractant in Matrigel® transwell assay. IgG1 treatment is used as an 826 
isotype control. Results are presented as number of invasive cells per field  normalized 827 
by the untreated control. Representative experiment of n=3. Mann-Whitney test (n>19 828 
fields). F) Quantification of invasive βTC4 cells per field in the presence of the 829 
conditioned media of parental, sh Sema4D, sh CD72, sh PlexinB2 and sh NS (non-830 
silencing control) RAW 264 cells used as chemoattractant in Matrigel® transwell assay. 831 
Results are presented as number of invasive cells per field  normalized by the parental 832 
control. Representative experiment of n=3. Mann-Whitney test (n>20 fields).  833 
 834 
   18 
 
Figure 6. SDF1/CXCR4 axis is responsible for promoting invasion after anti-835 
Sema4D treatment and is present in vivo. A) Levels of stromal cell-derived factor 1 836 
(SDF1) in supernatants of RAW 264 cells treated with IgG1 or anti-Sema4D. Anti-837 
Sema4D added medium was used as a control. T-test (n=4). B) Quantification of SDF1 838 
protein release by ELISA analysis of conditioned media from control and anti-Sema4D 839 
treated RAW parental and sh Sema4D cells. Results are presented as ng of SDF1 per 840 
total protein µg for each condition normalized by the untreated controls. Mann-Whitney 841 
test (n=3). C) Quantification of in vitro matrigel invasion assay of βTC4 cells in 842 
presence of basal medium, medium containing SDF1, AMD3100 or both. Results are 843 
presented as number of invasive cells per field normalized by the basal control. 844 
Representative experiment of n=3. Mann-Whitney test (n≥ 30 fields). D) Quantification 845 
of in vitro matrigel invasion assay in which βTC4 cells were incubated with conditioned 846 
media from RAW 264 cells untreated or treated with IgG1 or anti-Sema4D in presence 847 
of SDF1 or its AMD3100. Results are presented as number of invasive cells per field  848 
normalized by the untreated control. Representative experiment of n=3. Mann-Whitney 849 
test (n≥ 30 fields). E)  Immunohistochemistry (left) and quantification (right) of the 850 
incidence of CXR4 expressing tumors in control and anti-Sema4D treated mice. Chi-851 
square test (n>17 tumors). F) Immunohistochemistry (left) and quantification (right) of 852 
the number of SDF1 positive round intratumoral cells per field in control and anti-853 
Sema4D treated mice. Mann-Whitney test (n>85 tumors). G) Incidence of SDF1 854 
expressing tumors according to the invasive capacity of the tumor fronts and the 855 
treatment regime. H) Quantification of the number of SDF1 positive Sema4D positive 856 
cells per total number of Sema4D positive cells per tumor field of control and anti-857 
Sema4D treated mice. Mann-Whitney test (n>17 tumors). 858 
 859 
Figure 7. Clinical validation of the Sema4D-CXCR4 signaling axis. Gene 860 
expression analysis of A) SEMA4D, B) SDF1 and C) CXCR4 genes in normal 861 
pancreas islet, non-malignant and malignant primary tumor and their derived 862 
metastases from a clinical set of PanNET patients samples (GSE73338). Mann-863 
Whitney test (n≥7). D) Correlation analysis of CXCR4 and Sema4D gene expression in 864 
non-malignant and malignant primary tumors from a clinical set of PanNET patients 865 
samples (GSE73338). Spearman’s correlation p (n≥26). E) Quantification of the 866 
number of migrated THP-1 human macrophage cells per field in untreated and anti-867 
Sema4D treatment conditions. Results are presented as number of migratory cells per 868 
field normalized by the untreated control. Mann-Whitney test (n≥30). F) Quantification 869 
of SDF1 protein release by ELISA analysis of conditioned media from control and anti-870 
Sema4D treated THP-1 cells. Results are presented as ng of SDF1 per total protein µg 871 
for each condition normalized by the untreated control. Mann-Whitney test (n=3). G) 872 
Proposed model for anti-Sema4D derived malignization. Targeting of macrophage 873 
derived Sema4D produces macrophage activation and secretion of pro-invasive 874 
molecules such as SDF1. Secreted SDF1 is latter bound to its CXCR4 receptor in 875 
tumor cells to drive tumor cell invasion. Figure was created using Servier Medical Art 876 
according to a Creative Commons Attribution 3.0 Unported License guidelines 3.0 877 
(https://creativecommons.org/licenses/by/3.0/). Simplification and color changes were 878 
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